Get the Stockscreener App
2.64
3.94%
0.10
After Hours:
2.61
-0.03
-1.14%
Atossa Therapeutics Inc stock is traded at $2.64, with a volume of 57,039.
It is up +3.94% in the last 24 hours and up +15.03% over the past month.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
See More
Previous Close:
$2.54
Open:
$2.56
24h Volume:
57,039
Relative Volume:
0.38
Market Cap:
$26.35M
Revenue:
-
Net Income/Loss:
$-37.64M
P/E Ratio:
-0.6041
EPS:
-4.3698
Net Cash Flow:
$-33.40M
1W Performance:
-5.38%
1M Performance:
+15.03%
6M Performance:
-37.29%
1Y Performance:
-77.36%
1-Day Range:
$2.45
$2.65
1-Week Range:
$2.44
$2.7827
52-Week Range:
$1.70
$19.35
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Name
Atossa Therapeutics Inc
Sector
Industry
Phone
206.588.0256
Address
1448 NW MARKET STREET, SEATTLE, WA
Compare ATOS vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
2.64 | 25.85M | 0 | -37.64M | -33.40M | -4.3698 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-18 | Initiated | Maxim Group | Buy |
Atossa Therapeutics Inc Stock (ATOS) Latest News
Atossa Therapeutics advances investigational Z-endoxifen research for broader DMD applications - Traders Union
We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate - Sahm
Daily Brief Health Care: Modern Dental Group, Suzhou Zelgen Biopharmaceuticals, Blue Water Vaccines, Ono Pharmaceutical, Ensysce Biosciences , Dyadic International , Atossa Therapeutics and more - Smartkarma
ATOS: Multiple Catalysts Converge in 2H26 - Smartkarma
Atossa Therapeutics, Inc. (ATOS) Latest Stock News & Headlines - Yahoo Finance
Atossa Therapeutics pursues ESR1 mutation research to tackle endocrine resistance in breast cancer - Traders Union
Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS), Corvus Pharmaceuticals (CRVS) and Perspective Therapeutics (CATX) - The Globe and Mail
Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Atossa Therapeutics shifts clinical focus to pre-surgical breast cancer patients - Traders Union
Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Atossa Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Weekly Recap: Q2 net loss, financing and (Z)-endoxifen Phase 2 progress - TradingView
Atossa Therapeutics reports Q2 2026 results, ad... - Pluang
Atossa Therapeutics (ATOS) Dips 2.48% to $2.36 as Stock Tests Key Support ZoneLast Point Resistance - vinanet.vn
Atossa Therapeutics Inc expected to post a loss of $1.08 a shareEarnings Preview - TradingView
Atossa Therapeutics investigates (Z)-endoxifen for McCune-Albright syndrome and endocrine disorders - tradersunion.com
Atossa Therapeutics (ATOS) Advances Clinical Pipeline Amid Valua - GuruFocus
Form 8K Atossa Therapeutics Inc For: 7 August By Investing.com - Investing.com Canada
Atossa Therapeutics Q2 net loss widens on lower interest income - TradingView
Atossa Therapeutics reports Q2 2026 net loss $8.5M, cash $26.1M; advances (Z)-endoxifen programs - TradingView
ATOS: Q2 2026 net loss was $8.5M; (Z)-endoxifen programs advanced and $4.5M in new capital raised - TradingView
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - PR Newswire
ATOSSA THERAPEUTICS, INC. Q2 2026: Net loss $(8.49M), EPS $(0.95) — 10-Q Summary - TradingView
Atossa Therapeutics (NASDAQ: ATOS) posts $18.1M loss, flags going concern risk - Stock Titan
Atossa Therapeutics strengthens pipeline with new data on Z-endoxifen breast cancer therapy - tradersunion.com
Calendrier des fractionnements d'actions pour: - Yahoo Finance France
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
Atossa Therapeutics advances rare disease pipeline with (Z)-endoxifen strategy - Traders Union
ATOS Q1 2026 Earnings: EPS Surprise of 82.23% Narrows Loss Despite No Revenue; Stock Down 5.48%Financial Health Score - vinanet.vn
Atossa Therapeutics advances biomarker-driven Z-endoxifen treatment for breast cancer - Traders Union
Atossa Therapeutics (ATOS) Focuses on Execution Amid Challenging Valuation and Mixed Guru Interest - GuruFocus
Atossa study shows preclinical activity in breast cancer models By Investing.com - Investing.com South Africa
Atossa Therapeutics (ATOS) Unveils Promising Preclinical Breast Cancer Study Amidst Challenging Valuation - GuruFocus
Atossa study shows preclinical activity in breast cancer models - Investing.com
Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer - Morningstar
Atossa Therapeutics Inc (ATOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Atossa Therapeutics (ATOS) Gains 4.6%: Biotech Stock Tests Key ResistanceETF Flow - dars.gov.et
TradingKey - TradingKey
Atossa Therapeutics Inc (ATOS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ATOS Q1 2026 Earnings: EPS Surprise of 82.23% Amidst Pre-Revenue StageQuarterly Earnings - vinanet.vn
Atossa Therapeutics Inc (ATOS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ATOS|Atossa Therapeutics Inc|Price:2.295|Chg%:-0.115 - TradingKey
ATOSSA THERAPEUTICS, INC. advances omics and organoid research in rare cancer field - Traders Union
Atossa Therapeutics (ATOS) Unveils Promising Data for (Z)-Endoxi - GuruFocus
Atossa Therapeutics (ATOS) Unveils Promising Data for (Z)-Endoxifen in Rare Disease Treatment - GuruFocus
Atossa Therapeutics highlights (Z)-endoxifen's dual action for rare McCune-Albright Syndrome treatment. - Pluang
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers - PR Newswire
ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug - Stocktwits
NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The News-Press
Price to sales forward of Atossa Therapeutics, Inc. – DUS:YAG - TradingView
Enterprise value to revenue forward of Atossa Therapeutics, Inc. – DUS:YAG - TradingView
Atossa Therapeutics Inc Stock (ATOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):